Contact Us
Certain formulation components in vaccine products (e.g., surfactants), renders the endotoxin undetectable by standard LAL assays even though it remains biologically active.
Menu
Vaccines represent one of the most significant achievements in modern biotechnology, designed to elicit a protective immune response against specific pathogens. These biological products range from traditional inactivated or live-attenuated viruses to sophisticated recombinant subunits and modern mRNA-lipid nanoparticle (LNP) platforms. A critical aspect of vaccine safety is the control of pyrogenic impurities, specifically bacterial endotoxins. Our Endotoxin Testing for Vaccines helps you obtain high-quality recombinant proteins and streamline clinical trial processes through advanced recombinant DNA technology and high-throughput screening platforms. Creative Biolabs provides the precision required to accelerate your drug discovery and ensure uncompromised safety for every dose.
Fig.1 The types of vaccines.1
Vaccine endotoxin oversight is rigorous and distinct from standard injectables. Vaccines are primarily governed by lot-release specifications established during clinical trials. Under CFR 610.13, certain vaccines may bypass standard USP pyrogen tests if safety is proven through validated alternatives.
Testing vaccines for endotoxin is rarely a straightforward process due to the biological complexity of the product matrix. Creative Biolabs identifies several recurring industry hurdles:
Certain formulation components in vaccine products (e.g., surfactants), renders the endotoxin undetectable by standard LAL assays even though it remains biologically active.
Adjuvants like aluminum hydroxide are known to adsorb endotoxins, which can interfere with the enzymatic cascade of the assay and lead to inaccurate recovery.
Creative Biolabs utilizes a multi-tiered analytical approach to overcome the limitations of traditional testing. Our solutions are tailored to the specific modality of your vaccine:
To eliminate false positives caused by (1→3)-beta-glucans, we utilize rFC technology. This single-enzyme activation pathway is more specific than traditional LAL and aligns with the latest global pharmacopoeial standards.
We address LER by implementing proprietary de-masking techniques. By using specialized dispersing agents and optimizing sample preparation, we free the LPS from formulation traps, ensuring recovery of positive product controls (PPC).
We perform extensive hold-time studies to ensure endotoxin stability throughout your manufacturing window. Using advanced imaging and deep learning algorithms, we can also monitor the distribution of your product to critical areas like the draining lymph nodes.
Creative Biolabs is a leader in biopharmaceutical safety with a track record of supporting complex vaccine candidates. Creative Biolabs provides expert Endotoxin Testing for Vaccines with the latest in recombinant technology to solve complex challenges like LER and matrix interference. From preclinical research to clinical lot release, we are your partner in biological safety. Contact us to discuss your project requirements.
Yes. rFC is now recognized as a compendial-equivalent method in Europe (Ph. Eur. 2.6.32) and is accepted by other global regulators, provided the method is appropriately validated for your specific vaccine matrix.
For samples that interfere with optical readings, Creative Biolabs utilizes the Gel Clot technique. This method is robust against turbidity and allows for reliable testing of nanoparticle and microparticle suspensions.
We utilize de-masking protocols that involve specific additives and optimized dilutions to restore the detectability of LPS monomers that have been "hidden" by surfactants or buffers in your formulation.
Reference
Contact Us
